Agios Pharmaceuticals | AGIO - Sales Revenues


Agios Pharmaceuticals reported $19.97M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Astellas Pharma JPY 571.21B 46.89B Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025